2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 324

Adherence to Guideline Directed Management of Gout Among VA Providers

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 321

Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 691

Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 120

Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 328

Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 674

Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 639

African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 257

Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 581

Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 353

Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 25

Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 27

Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 66

Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 725

Amniotic Membrane Dressings Provide an Effective Treatment for Systemic Sclerosis Digital Ulcers

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 4

AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine

Cytokines & Cell Trafficking Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].